Joanne McEntee
Overview
Explore the profile of Joanne McEntee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fleeman N, Houten R, Nevitt S, Mahon J, Beale S, Boland A, et al.
Health Technol Assess
. 2024 Sep;
28(49):1-190.
PMID: 39252678
Background: Renal cell carcinoma is the most common type of kidney cancer, comprising approximately 85% of all renal malignancies. Patients with advanced renal cell carcinoma are the focus of this...
2.
Bresnahan R, Houten R, Greenhalgh J, Nevitt S, Mahon J, Beale S, et al.
Pharmacoecon Open
. 2023 May;
7(4):525-536.
PMID: 37195551
As part of the Single Technology Appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited Apellis Pharmaceuticals/Sobi to submit evidence for the clinical and cost...
3.
Spoors J, Miners A, Cairns J, Palnoch D, Summerfield A, McEntee J, et al.
BioDrugs
. 2020 Nov;
35(1):1-5.
PMID: 33226582
Advanced therapy medicinal products (ATMPs) are a dynamic and current topic for healthcare systems, with new products progressing to market at an increasing rate. ATMPs highlight the growing gap between...
4.
Houten R, Greenhalgh J, Mahon J, Nevitt S, Beale S, Boland A, et al.
Pharmacoecon Open
. 2020 Apr;
5(1):13-22.
PMID: 32291725
As part of the Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited Pierre Fabre to submit evidence for the clinical and cost-effectiveness of encorafenib...
5.
Stainthorpe A, Fleeman N, Houten R, Chaplin M, Boland A, Beale S, et al.
Pharmacoecon Open
. 2020 Mar;
4(4):563-574.
PMID: 32207075
As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Takeda UK Ltd to submit clinical- and cost-effectiveness evidence for brentuximab vedotin (BV)...
6.
Fleeman N, Mahon J, Nevitt S, Duarte R, Boland A, Kotas E, et al.
Pharmacoecon Open
. 2019 Jun;
3(4):453-461.
PMID: 31240690
As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of cenegermin (OXERVATE, Dompé) to submit evidence for the...
7.
Fleeman N, Bagust A, Duarte R, Richardson M, Nevitt S, Boland A, et al.
Pharmacoecon Open
. 2019 Feb;
3(3):293-302.
PMID: 30742256
Eribulin is a recommended treatment option for locally advanced or metastatic breast cancer (LABC/MBC) in adults whose disease has progressed after at least two chemotherapy regimens. The National Institute for...
8.
Lambe T, Duarte R, Mahon J, Nevitt S, Greenhalgh J, Boland A, et al.
Pharmacoeconomics
. 2018 Oct;
37(3):345-357.
PMID: 30328051
As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Merck to submit evidence for the clinical and cost effectiveness of cladribine tablets...
9.
Fleeman N, Abdulla A, Bagust A, Beale S, Richardson M, Stainthorpe A, et al.
Pharmacoeconomics
. 2017 Nov;
36(3):289-299.
PMID: 29178025
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Shire Pharmaceuticals) of pegylated liposomal irinotecan hydrochloride trihydrate (liposomal irinotecan) to submit clinical and cost-effectiveness evidence for its...
10.
Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Fleeman N, et al.
Health Technol Assess
. 2015 Apr;
19(29):1-130.
PMID: 25896573
Background: Acute coronary syndromes (ACSs) are life-threatening conditions associated with acute myocardial ischaemia. There are three main types of ACS: ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial...